SVP, Strategy & Investor Relations
– Total Revenues of $658.7 million, Cabozantinib Franchise U.S. Net Product Revenues of $604.9 million
- Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2026, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones.
“Exelixis continued to execute across all of our key priorities in the third quarter, driving the cabozantinib franchise forward while preparing for zanzalintinib as our next potential franchise opportunity,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis. “The zanzalintinib development program gained further momentum as the organization focused on trial initiations, enrollment progress for ongoing studies and in- depth planning for the next wave of new pivotal trials. The enthusiasm around the zanzalintinib franchise continues, and we look forward to sharing more progress when appropriate. As we execute on our priorities, we remain disciplined in our deployment of capital as we invest in our R&D portfolio, return value to shareholders through our stock repurchase program and actively evaluate external innovation opportunities that can strengthen our pipeline and create long-term value for patients and all of our stakeholders.”
for the quarter ended September 30, 2026 were $658.7 million, as compared to $597.8 million for the comparable period in 2025.
Total revenues for the quarter ended September 30, 2026 included net product revenues of $604.9 million, as compared to $542.9 million for the comparable period in 2025. The increase in net product revenues was primarily due to an increase in sales volume and an increase in average net selling price.
Collaboration revenues, composed of license revenues and collaboration services revenues, were $53.8 million for the quarter ended September 30, 2026, as compared to $54.8 million for the comparable period in 2025. The decrease in collaboration revenues was primarily related to lower milestone-related revenues recognized in the quarter and lower development cost reimbursements earned, partially offset by
higher royalty revenues for the sales of cabozantinib outside the U.S. generated by Exelixis’ collaboration partner Ipsen Pharma SAS (Ipsen).
for the quarter ended September 30, 2026 were $209.5 million, as compared to $199.2 million for the comparable period in 2025. The increase in research and development expenses was primarily related to increases in personnel expenses and clinical trial costs, partially offset by a decrease in license and other collaboration costs.
for the quarter ended September 30, 2026 were $154.6 million, as compared to $123.7 million for the comparable period in 2025. The increase in selling, general and administrative expenses was primarily related to increases in personnel expenses, marketing activities, and legal and advisory fees.
for the quarter ended September 30, 2026 was $64.7 million, as compared to $58.8 million for the comparable period in 2025.
for the quarter ended September 30, 2026 was $218.1 million, or $0.88 per share, basic and $0.85 per share, diluted, as compared to GAAP net income of $193.6 million, or $0.72 per share, basic and $0.69 per share, diluted, for the comparable period in 2025. GAAP net income per share for the quarter ended September 30, 2026 was favorably impacted by lower weighted-average common shares outstanding for the quarter ended September 30, 2026, as compared to the comparable period in 2025, as a result of the stock repurchase programs.
for the quarter ended September 30, 2026 was $240.2 million, or $0.97 per share, basic and $0.94 per share, diluted, as compared to non-GAAP net income of $217.9 million, or $0.81 per share, basic and $0.78 per share, diluted, for the comparable period in 2025.
To supplement Exelixis’ financial results presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Exelixis presents non-GAAP net income (and the related per share measures), which excludes from GAAP net income (and the related per share measures) stock-based compensation, adjusted for the related income tax effect for all periods presented.
Exelixis believes that the presentation of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors. In particular, Exelixis believes that these non-GAAP financial measures, when considered together with its financial information prepared in accordance with GAAP, can enhance investors’ and analysts’ ability to meaningfully compare Exelixis’ results from period to period, and to identify operating trends in Exelixis’ business. Exelixis has excluded stock-based compensation, adjusted for the related income tax effect, because it is a non- cash item that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. Exelixis also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate its business and to make operating decisions.
These non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Exelixis encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP financial information and the reconciliation between these presentations, to more fully understand Exelixis’ business. Reconciliations between GAAP and non-GAAP results are presented in the tables of this release.
Exelixis is providing the following updated financial guidance for fiscal year 2026. Net product and total revenues guidance do not currently reflect any revenues resulting from a potential U.S. regulatory approval and commercial launch of zanzalintinib for the treatment of patients with previously treated metastatic colorectal cancer (CRC). The U.S. Food and Drug Administration (FDA) is currently reviewing Exelixis' New Drug Application (NDA) for this proposed indication, when used in combination with atezolizumab (Tecentriq ® ).
Current Guidance Previous Guidance (provided on October (provided on August 5, 29, 2026) 2026) ────────────────────────────────────────────────────────────────────────────── Total revenues $2.500 billion - $2.550 $2.500 billion - $2.550 billion billion Net product revenues $2.300 billion - $2.350 $2.300 billion - $2.350 billion(1) billion(1) Cost of goods sold, % of net product ~4% 3.5% - 4.5% revenues Research and $825 million - $875 $825 million - $875 development expenses million(2) million(2) Selling, general and $575 million - $625 $575 million - $625 administrative million(3) million(3) expenses Effective tax rate 16% - 18% 21% - 23%
(1) Exelixis’ 2026 net product revenues guidance range includes the impact of a U.S. wholesale acquisition cost increase of 3.0% for CABOMETYX and COMETRIQ effective January 1, 2026.
Net product revenues generated by the cabozantinib franchise in the U.S. were $604.9 million during the third quarter of 2026, with net product revenues of $603.2 million from CABOMETYX ® (cabozantinib) and $1.8 million from COMETRIQ ® (cabozantinib). Based upon cabozantinib-related net product revenues generated by Exelixis’ collaboration partners, Ipsen and Takeda Pharmaceutical Company Limited, during the quarter ended September 30, 2026, Exelixis earned $51.8 million in royalty revenues.
Ongoing Regulatory Review of Zanzalintinib in Combination with Atezolizumab (Tecentriq
) for Previously Treated Metastatic CRC with Prescription Drug User Fee Act (PDUFA) Target Action Date of March 3, 2027. The U.S. FDA is actively reviewing Exelixis’ NDA for zanzalintinib, in combination with atezolizumab, for the treatment of patients with metastatic CRC who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, and, if RAS wild-type, an anti-epidermal growth factor receptor (EGFR) therapy. In September 2026, Exelixis announced that the agency extended the review period for its NDA by three months after the company submitted updated safety and efficacy data in response to an FDA information request. The updated PDUFA target action date is March 3, 2027. The NDA is based on positive results from the phase 3 STELLAR-303 pivotal trial evaluating zanzalintinib in combination with atezolizumab versus regorafenib in previously treated non-microsatellite instability (non-MSI)-high metastatic CRC. As previously announced in June 2025, STELLAR-303 met one of its dual primary endpoints, overall survival (OS) in the intention-to-treat population, which included all randomized patients regardless of the presence of active liver metastases. In June 2026, Exelixis announced results from the final analysis of the other dual primary endpoint, OS in the non-liver metastases (NLM) subpopulation, showing a non-statistically significant trend in OS favoring zanzalintinib in combination with atezolizumab. Exelixis intends to present detailed findings from the NLM subpopulation at a future medical conference.
Initiation of Phase 3 STELLAR-316 Pivotal Trial in Collaboration with Merck and Natera. In August 2026, Exelixis initiated the phase 3 STELLAR-316 pivotal trial evaluating zanzalintinib, with and without KEYTRUDA QLEX ™ (pembrolizumab and berahyaluronidase alfa-pmph), in patients with resected stage II/III CRC who,
following definitive therapy, have tested positive for molecular residual disease (MRD+) and have no radiographic evidence of disease. The primary endpoint of STELLAR-316 is disease-free survival, with key secondary endpoints including circulating tumor DNA clearance. Exelixis is sponsoring the study; Merck, known as MSD outside of the United States and Canada, is supplying KEYTRUDA QLEX injection for subcutaneous administration; and Natera, a global leader in cell-free DNA and precision medicine, is providing its Signatera ™ assay to identify MRD+ patients for trial enrollment. The study is currently enrolling.
Enrollment Progressing Rapidly for Phase 2/3 STELLAR-311 Pivotal Trial. Exelixis is continuing to actively enroll patients in the phase 2/3 STELLAR-311 pivotal trial. STELLAR-311 is evaluating zanzalintinib versus everolimus as a first oral therapy in patients with advanced neuroendocrine tumors (NET), regardless of site of origin, who have received up to one prior line of therapy. The primary endpoint of the trial is progression-free survival (PFS) per RECIST 1.1 as assessed by blinded independent central review.
Topline Results for Phase 3 STELLAR-304 Pivotal Trial Expected in First Quarter of 2027. Today, Exelixis announced it expects topline results from the phase 3 STELLAR-304 pivotal trial in the first quarter of 2027. STELLAR-304 is evaluating zanzalintinib in combination with nivolumab versus sunitinib in previously untreated patients with advanced non-clear cell renal cell carcinoma (nccRCC). The primary endpoints of the trial are PFS as assessed by blinded independent radiology committee and objective response rate (ORR) per RECIST 1.1, with OS as the secondary endpoint.
Phase 3 LITESPARK-033 and LITESPARK-034 Pivotal Trials as Part of Clinical Development Collaboration with Merck. The Merck-sponsored global phase 3 pivotal trials, LITESPARK-033 and LITESPARK-034, are active and enrolling patients as part of Exelixis’ clinical development collaboration with Merck evaluating zanzalintinib in combination with WELIREG ® (belzutifan) in advanced renal cell carcinoma (RCC). LITESPARK-033, initiated by Merck in December 2025, is evaluating the combination of zanzalintinib and WELIREG versus cabozantinib in first-line advanced RCC following an immunotherapy administered in the adjuvant setting. LITESPARK-034, initiated by Merck in April 2026, is evaluating zanzalintinib in combination with WELIREG versus WELIREG and placebo in second- line or later advanced RCC patients who have progressed on or after both programmed death-1/ligand 1 (PD-1/L1) and vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI) therapies in sequence or in combination.
Enrollment Ongoing in Metastatic Bladder Cancer and Metastatic Castration- Resistant Prostate Cancer (mCRPC) Expansion Cohorts of Phase 1b/2 STELLAR-002 Study. In August 2026, Exelixis announced the initiation of metastatic bladder cancer and mCRPC expansion cohorts as part of the ongoing phase 1b/2 STELLAR-002 study. The STELLAR-002 expansion cohorts are evaluating zanzalintinib monotherapy in patients with metastatic bladder cancer who have progressed following treatment with enfortumab vedotin and pembrolizumab, as well as zanzalintinib in combination with docetaxel in mCRPC patients with measurable disease.
Initiation of Phase 2 STELLAR-202 Trial in Squamous Non-small Cell Lung Cancer (NSCLC). In October 2026, Exelixis initiated STELLAR-202, a phase 2 trial evaluating zanzalintinib in combination with pembrolizumab in the maintenance setting in squamous NSCLC. The primary endpoint of the trial is six-month PFS (PFS-6), with secondary endpoints including safety, PFS, OS, ORR and duration of response (DOR). The study is currently enrolling.
Enrollment Ongoing in Phase 2 STELLAR-201 Trial in Recurrent Meningioma. Enrollment is ongoing for the phase 2 STELLAR-201 trial. Initiated in April 2026, STELLAR-201 is evaluating zanzalintinib in patients with recurrent Grade I/II/III meningioma with relapse or progression following radiation and/or surgery or those who are not candidates for these therapies. The primary endpoint of the trial is ORR, with secondary endpoints
including PFS, DOR and OS. Pending favorable results, the trial represents an opportunity for zanzalintinib to become the first and only systemic therapy for this form of meningioma, the most common primary intracranial neoplasm for which there are currently no approved systemic therapies.
In May 2026, Exelixis’ Board of Directors authorized the repurchase of up to $750 million of the company’s outstanding common stock before December 31, 2027 (May 2026 SRP). As of the end of the third quarter of 2026, Exelixis repurchased $402.1 million of the company’s outstanding common stock, at an average price of $54.03 per share under the May 2026 SRP. Since Exelixis’ Board of Directors authorized the first SRP in March 2023, Exelixis has repurchased a total of $3.2 billion of the company’s outstanding common stock, retiring 97.8 million shares, at an average price of $32.25 per share, as of the end of the third quarter of 2026.
Stock repurchases under the May 2026 SRP may be made from time to time through a variety of methods, which may include open market purchases, in block trades, Rule 10b5-1 trading plans, accelerated share repurchase transactions, exchange transactions, or any combination of such methods. The timing and amount of any stock repurchases under the program will be based on a variety of factors, including ongoing assessments of the capital needs of the business, alternative investment opportunities, the market price of our common stock and general market conditions. The program does not obligate us to acquire any amount of our common stock, and may be modified, suspended or discontinued at any time without prior notice.
Announcement of Settlement with Azurity Pharmaceuticals, Inc. (Azurity). On October 28, 2026, we entered into a settlement and license agreement with Azurity (the Azurity Settlement Agreement) to resolve the Azurity litigation. Pursuant to the terms of the Azurity Settlement Agreement, we will grant Azurity a license to market its proposed 505(b)(2) NDA product in the U.S. beginning on December 1, 2030, if approved by the FDA and subject to conditions and exceptions customary for agreements of this type. The effective date for the proposed generic cabozantinib products where we have a settlement and license agreement remains January 1, 2031, subject to conditions and exceptions customary for agreements of this type.
Announcement on Patent Litigation Trial Appeal with MSN Laboratories. In August 2026, the U.S. Court of Appeals for the Federal Circuit (Court of Appeals) affirmed a favorable district court decision in Exelixis’ patent lawsuit against MSN Laboratories Private Limited et al. (MSN), upholding the validity of U.S. Patent Nos. 11,091,439, 11,091,440 and 11,098,015. As a result, the effective date of any final FDA approval of MSN’s Abbreviated New Drug Application (ANDA) shall not be a date earlier than January 15, 2030, subject to any further appellate proceedings, applicable regulatory exclusivity, and the outcome of separate consolidated litigation involving U.S. Patent No. 12,128,039, with a trial scheduled for November 2026. The Court of Appeals also dismissed as moot MSN’s appeal relating to the validity of U.S. Patent No. 11,298,349.
Exelixis uses a 52- or 53-week fiscal year that generally ends on the Friday closest to December 31. For convenience, references in this press release as of and for the fiscal periods ended October 2, 2026 and October 3, 2025, are indicated as being as of and for the periods ended September 30, 2026 and September 30, 2025, respectively.
Exelixis management will discuss the company’s financial results for the third quarter of 2026 and provide a general business update during a conference call beginning at 5:00 p.m. ET / 2:00 p.m. PT today, Thursday, October 29, 2026.
To access the conference call, please register using this link . Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. A webcast replay of the conference call will also be archived on www.exelixis.com for one year.
Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules and biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our pipeline of franchise molecules, including our novel oral kinase inhibitor zanzalintinib, and to extend the impact of our flagship commercial product, CABOMETYX ® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com , follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn.
This press release contains forward-looking statements, including, without limitation, statements related to: Exelixis’ belief in zanzalintinib as its next potential franchise opportunity; Exelixis’ focus on disciplined capital deployment, including investing in its R&D portfolio, returning value to shareholders through its stock repurchase programs, and evaluating external innovation opportunities that may strengthen its pipeline and create long-term value; Exelixis’ clinical development plans for zanzalintinib, including progress on additional pivotal trials and plans to share progress when appropriate; Exelixis’ plans to present detailed findings from the NLM subpopulation for STELLAR-303 at a future medical conference; the anticipated timing of topline results from STELLAR-304; Exelixis’ belief that, pending favorable results, STELLAR-201 represents an opportunity for zanzalintinib to become the first and only systemic therapy for recurrent Grade I/II/III meningioma; Exelixis’ expectations regarding the timing and outcome of FDA review of its NDA for zanzalintinib in combination with atezolizumab for previously treated metastatic CRC; Exelixis’ expectations regarding the implications of the appellate ruling in its patent litigation with MSN for the timing of any final FDA approval and U.S. commercial launch of MSN’s proposed ANDA product, subject to any further appellate proceedings, applicable regulatory exclusivity, and the outcome of its separate consolidated litigation with MSN; Exelixis’ expectations regarding the licenses to be granted and the timing of U.S. market entry for Azurity’s proposed 505(b)(2) NDA product and proposed generic cabozantinib products under its settlement and license agreements, subject to FDA approval and the applicable terms, conditions, and exceptions of those agreements; Exelixis’ updated FY 2026 financial guidance; the timing and amount of any future stock repurchases under the May 2026 SRP and the potential modification, suspension, or discontinuation of the program; Exelixis’ scientific pursuit to create transformational treatments that give more patients hope for the future; and other statements that are not historical facts. Any statements that refer to expectations, projections, or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis’ current plans, assumptions, beliefs, expectations, estimates, and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the degree of market acceptance of CABOMETYX and other Exelixis products in the indications for which they are approved and in the territories where they are approved, and Exelixis’ and its partners’ ability to obtain or maintain coverage and reimbursement for these products; the effectiveness of CABOMETYX and other Exelixis products in comparison to competing products; complexities and the unpredictability of regulatory review and approval processes in the U.S. and elsewhere, including the timing and outcome of FDA review of Exelixis’ NDA for zanzalintinib in combination with atezolizumab for
previously treated metastatic CRC and the risk that the FDA may require additional information or analyses, further extend its review, or may not approve the NDA in a timely fashion, if at all; the level of costs associated with Exelixis’ commercialization, research and development, in-licensing or acquisition of product candidates, and other activities; Exelixis’ ability to identify, evaluate and successfully execute external innovation and other business development opportunities and to realize the anticipated benefits of any such opportunities; Exelixis’ ability to maintain and scale adequate sales, marketing, market access and product distribution capabilities for its products or to enter into and maintain agreements with third parties to do so; the availability of data at the referenced times; the potential failure of cabozantinib, zanzalintinib and other Exelixis product candidates, both alone and in combination with other therapies, to demonstrate safety and/or efficacy in clinical testing; uncertainties inherent in the drug discovery and product development process; Exelixis’ dependence on its relationships with its collaboration partners, including their pursuit of regulatory approvals for partnered compounds in new indications, their adherence to their obligations under relevant collaboration agreements and the level of their investment in the resources necessary to complete clinical trials or successfully commercialize partnered compounds in the territories where they are approved; Exelixis’ continuing compliance with applicable legal and regulatory requirements; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating cabozantinib, zanzalintinib and other Exelixis product candidates; Exelixis’ dependence on third-party vendors for the development, manufacture and supply of its products and product candidates; Exelixis’ ability to protect its intellectual property rights; market competition, including the potential for competitors to obtain approval for and market generic versions, or other products that compete with, of Exelixis’ marketed products; changes in economic and business conditions, including as a result of changing trade policies and tariffs and the related uncertainty thereof; and other factors detailed from time to time under the caption “Risk Factors” in Exelixis’ most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis’ other future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law. Exelixis, the Exelixis logo, CABOMETYX and COMETRIQ are registered U.S. trademarks of Exelixis, Inc.
Tecentriq ® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.
WELIREG ® and KEYTRUDA QLEX ™ are registered trademarks of Merck Sharp & Dohme LLC,
(1) Non-cash stock-based compensation used for GAAP reporting in accordance with Accounting Standards Codification Topic 718, Compensation—Stock Compensation .
Full text with the tables
Exhibit 99.1
Contacts:
Chris Senner
Chief Financial Officer
Exelixis, Inc.
650-837-7240
[email protected]
Andrew Peters
SVP, Strategy & Investor Relations
Exelixis, Inc.
650-837-7248
[email protected]
Exelixis Announces Third
Quarter 2026
Financial Results and Provides Corporate Update
– Total Revenues of $658.7 million, Cabozantinib Franchise U.S. Net Product
Revenues of $604.9 million
–
– GAAP Diluted EPS of $0.85, Non-GAAP Diluted EPS of $0.94 –
– Conference Call and Webcast Today at 5:00 PM ET –
ALAMEDA, Calif.
–
October 29, 2026
- Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third
quarter of 2026, provided an update on progress toward achieving key corporate
objectives, and outlined its commercial, clinical and pipeline development
milestones.
“Exelixis continued to execute across all of our key priorities in the third
quarter, driving the cabozantinib franchise forward while preparing for
zanzalintinib as our next potential franchise opportunity,” said Michael M.
Morrissey, Ph.D., President and Chief Executive Officer, Exelixis. “The
zanzalintinib development program gained further momentum as the organization
focused on trial initiations, enrollment progress for ongoing studies and in-
depth planning for the next wave of new pivotal trials. The enthusiasm around
the zanzalintinib franchise continues, and we look forward to sharing more
progress when appropriate. As we execute on our priorities, we remain
disciplined in our deployment of capital as we invest in our R&D portfolio,
return value to shareholders through our stock repurchase program and actively
evaluate external innovation opportunities that can strengthen our pipeline and
create long-term value for patients and all of our stakeholders.”
Third Quarter 2026
Financial Results
Total revenues
for the quarter ended September 30, 2026 were $658.7 million, as compared to
$597.8 million for the comparable period in 2025.
Total revenues for the quarter ended September 30, 2026 included net product
revenues of $604.9 million, as compared to $542.9 million for the comparable
period in 2025. The increase in net product revenues was primarily due to an
increase in sales volume and an increase in average net selling price.
Collaboration revenues, composed of license revenues and collaboration services
revenues, were $53.8 million for the quarter ended September 30, 2026, as
compared to $54.8 million for the comparable period in 2025. The decrease in
collaboration revenues was primarily related to lower milestone-related revenues
recognized in the quarter and lower development cost reimbursements earned,
partially offset by
- more -
Exelixis Third Quarter 2026 Financial Results
October 29, 2026 Page 2 of 9
──────────────────────────────────────────────────────────────
higher royalty revenues for the sales of cabozantinib outside the U.S. generated
by Exelixis’ collaboration partner Ipsen Pharma SAS (Ipsen).
Research and development expenses
for the quarter ended September 30, 2026 were $209.5 million, as compared to
$199.2 million for the comparable period in 2025. The increase in research and
development expenses was primarily related to increases in personnel expenses
and clinical trial costs, partially offset by a decrease in license and other
collaboration costs.
Selling, general and administrative expenses
for the quarter ended September 30, 2026 were $154.6 million, as compared to
$123.7 million for the comparable period in 2025. The increase in selling,
general and administrative expenses was primarily related to increases in
personnel expenses, marketing activities, and legal and advisory fees.
Provision for income taxes
for the quarter ended September 30, 2026 was $64.7 million, as compared to $58.8
million for the comparable period in 2025.
GAAP net income
for the quarter ended September 30, 2026 was $218.1 million, or $0.88 per share,
basic and $0.85 per share, diluted, as compared to GAAP net income of $193.6
million, or $0.72 per share, basic and $0.69 per share, diluted, for the
comparable period in 2025. GAAP net income per share for the quarter ended
September 30, 2026 was favorably impacted by lower weighted-average common
shares outstanding for the quarter ended September 30, 2026, as compared to the
comparable period in 2025, as a result of the stock repurchase programs.
Non-GAAP net income
for the quarter ended September 30, 2026 was $240.2 million, or $0.97 per share,
basic and $0.94 per share, diluted, as compared to non-GAAP net income of $217.9
million, or $0.81 per share, basic and $0.78 per share, diluted, for the
comparable period in 2025.
Non-GAAP Financial Measures
To supplement Exelixis’ financial results presented in accordance with U.S.
Generally Accepted Accounting Principles (GAAP), Exelixis presents non-GAAP net
income (and the related per share measures), which excludes from GAAP net income
(and the related per share measures) stock-based compensation, adjusted for the
related income tax effect for all periods presented.
Exelixis believes that the presentation of these non-GAAP financial measures
provides useful supplementary information to, and facilitates additional
analysis by, investors. In particular, Exelixis believes that these non-GAAP
financial measures, when considered together with its financial information
prepared in accordance with GAAP, can enhance investors’ and analysts’ ability
to meaningfully compare Exelixis’ results from period to period, and to identify
operating trends in Exelixis’ business. Exelixis has excluded stock-based
compensation, adjusted for the related income tax effect, because it is a non-
cash item that may vary significantly from period to period as a result of
changes not directly or immediately related to the operational performance for
the periods presented. Exelixis also regularly uses these non-GAAP financial
measures internally to understand, manage and evaluate its business and to make
operating decisions.
These non-GAAP financial measures are in addition to, not a substitute for, or
superior to, measures of financial performance prepared in accordance with GAAP.
Exelixis encourages investors to carefully consider its results under GAAP, as
well as its supplemental non-GAAP financial information and the reconciliation
between these presentations, to more fully understand Exelixis’ business.
Reconciliations between GAAP and non-GAAP results are presented in the tables of
this release.
- more -
Exelixis Third Quarter 2026 Financial Results
October 29, 2026 Page 3 of 9
──────────────────────────────────────────────────────────────
2026 Financial Guidance
Exelixis is providing the following updated financial guidance for fiscal year
2026. Net product and total revenues guidance do not currently reflect any
revenues resulting from a potential U.S. regulatory approval and commercial
launch of zanzalintinib for the treatment of patients with previously treated
metastatic colorectal cancer (CRC). The U.S. Food and Drug Administration (FDA)
is currently reviewing Exelixis' New Drug Application (NDA) for this proposed
indication, when used in combination with atezolizumab (Tecentriq ® ).
Current Guidance Previous Guidance
(provided on October (provided on August 5,
29, 2026) 2026)
──────────────────────────────────────────────────────────────────────────────
Total revenues $2.500 billion - $2.550 $2.500 billion - $2.550
billion billion
Net product revenues $2.300 billion - $2.350 $2.300 billion - $2.350
billion(1) billion(1)
Cost of goods sold, %
of net product ~4% 3.5% - 4.5%
revenues
Research and $825 million - $875 $825 million - $875
development expenses million(2) million(2)
Selling, general and $575 million - $625 $575 million - $625
administrative million(3) million(3)
expenses
Effective tax rate 16% - 18% 21% - 23%
____________________
(1) Exelixis’ 2026 net product revenues guidance range includes the impact of a
U.S. wholesale acquisition cost increase of 3.0% for CABOMETYX and COMETRIQ
effective January 1, 2026.
(2) Includes $50.0 million of non-cash stock-based compensation.
(3) Includes $75.0 million of non-cash stock-based compensation.
Cabozantinib Franchise Highlights
Net product revenues generated by the cabozantinib franchise in the U.S. were
$604.9 million during the third quarter of 2026, with net product revenues of
$603.2 million from CABOMETYX ® (cabozantinib) and $1.8 million from COMETRIQ ®
(cabozantinib). Based upon cabozantinib-related net product revenues generated
by Exelixis’ collaboration partners, Ipsen and Takeda Pharmaceutical Company
Limited, during the quarter ended September 30, 2026, Exelixis earned $51.8
million in royalty revenues.
Zanzalintinib GI Highlights
Ongoing Regulatory Review of Zanzalintinib in Combination with Atezolizumab
(Tecentriq
®
) for Previously Treated Metastatic CRC with Prescription Drug User Fee Act
(PDUFA) Target Action Date of March 3, 2027. The U.S. FDA is actively reviewing
Exelixis’ NDA for zanzalintinib, in combination with atezolizumab, for the
treatment of patients with metastatic CRC who have been previously treated with
fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, and, if RAS
wild-type, an anti-epidermal growth factor receptor (EGFR) therapy. In September
2026, Exelixis announced that the agency extended the review period for its NDA
by three months after the company submitted updated safety and efficacy data in
response to an FDA information request. The updated PDUFA target action date is
March 3, 2027. The NDA is based on positive results from the phase 3 STELLAR-303
pivotal trial evaluating zanzalintinib in combination with atezolizumab versus
regorafenib in previously treated non-microsatellite instability (non-MSI)-high
metastatic CRC. As previously announced in June 2025, STELLAR-303 met one of its
dual primary endpoints, overall survival (OS) in the intention-to-treat
population, which included all randomized patients regardless of the presence of
active liver metastases. In June 2026, Exelixis announced results from the final
analysis of the other dual primary endpoint, OS in the non-liver metastases
(NLM) subpopulation, showing a non-statistically significant trend in OS
favoring zanzalintinib in combination with atezolizumab. Exelixis intends to
present detailed findings from the NLM subpopulation at a future medical
conference.
Initiation of Phase 3 STELLAR-316 Pivotal Trial in Collaboration with Merck and
Natera. In August 2026, Exelixis initiated the phase 3 STELLAR-316 pivotal trial
evaluating zanzalintinib, with and without KEYTRUDA QLEX ™ (pembrolizumab and
berahyaluronidase alfa-pmph), in patients with resected stage II/III CRC who,
- more -
Exelixis Third Quarter 2026 Financial Results
October 29, 2026 Page 4 of 9
──────────────────────────────────────────────────────────────
following definitive therapy, have tested positive for molecular residual
disease (MRD+) and have no radiographic evidence of disease. The primary
endpoint of STELLAR-316 is disease-free survival, with key secondary endpoints
including circulating tumor DNA clearance. Exelixis is sponsoring the study;
Merck, known as MSD outside of the United States and Canada, is supplying
KEYTRUDA QLEX injection for subcutaneous administration; and Natera, a global
leader in cell-free DNA and precision medicine, is providing its Signatera ™
assay to identify MRD+ patients for trial enrollment. The study is currently
enrolling.
Enrollment Progressing Rapidly for Phase 2/3 STELLAR-311 Pivotal Trial. Exelixis
is continuing to actively enroll patients in the phase 2/3 STELLAR-311 pivotal
trial. STELLAR-311 is evaluating zanzalintinib versus everolimus as a first oral
therapy in patients with advanced neuroendocrine tumors (NET), regardless of
site of origin, who have received up to one prior line of therapy. The primary
endpoint of the trial is progression-free survival (PFS) per RECIST 1.1 as
assessed by blinded independent central review.
Zanzalintinib GU Highlights
Topline Results for Phase 3 STELLAR-304 Pivotal Trial Expected in First Quarter
of 2027. Today, Exelixis announced it expects topline results from the phase 3
STELLAR-304 pivotal trial in the first quarter of 2027. STELLAR-304 is
evaluating zanzalintinib in combination with nivolumab versus sunitinib in
previously untreated patients with advanced non-clear cell renal cell carcinoma
(nccRCC). The primary endpoints of the trial are PFS as assessed by blinded
independent radiology committee and objective response rate (ORR) per RECIST
1.1, with OS as the secondary endpoint.
Phase 3 LITESPARK-033 and LITESPARK-034 Pivotal Trials as Part of Clinical
Development Collaboration with Merck. The Merck-sponsored global phase 3 pivotal
trials, LITESPARK-033 and LITESPARK-034, are active and enrolling patients as
part of Exelixis’ clinical development collaboration with Merck evaluating
zanzalintinib in combination with WELIREG ® (belzutifan) in advanced renal cell
carcinoma (RCC). LITESPARK-033, initiated by Merck in December 2025, is
evaluating the combination of zanzalintinib and WELIREG versus cabozantinib in
first-line advanced RCC following an immunotherapy administered in the adjuvant
setting. LITESPARK-034, initiated by Merck in April 2026, is evaluating
zanzalintinib in combination with WELIREG versus WELIREG and placebo in second-
line or later advanced RCC patients who have progressed on or after both
programmed death-1/ligand 1 (PD-1/L1) and vascular endothelial growth factor
receptor-tyrosine kinase inhibitor (VEGFR-TKI) therapies in sequence or in
combination.
Enrollment Ongoing in Metastatic Bladder Cancer and Metastatic Castration-
Resistant Prostate Cancer (mCRPC) Expansion Cohorts of Phase 1b/2 STELLAR-002
Study. In August 2026, Exelixis announced the initiation of metastatic bladder
cancer and mCRPC expansion cohorts as part of the ongoing phase 1b/2 STELLAR-002
study. The STELLAR-002 expansion cohorts are evaluating zanzalintinib
monotherapy in patients with metastatic bladder cancer who have progressed
following treatment with enfortumab vedotin and pembrolizumab, as well as
zanzalintinib in combination with docetaxel in mCRPC patients with measurable
disease.
Zanzalintinib Development Program Highlights
Initiation of Phase 2 STELLAR-202 Trial in Squamous Non-small Cell Lung Cancer
(NSCLC). In October 2026, Exelixis initiated STELLAR-202, a phase 2 trial
evaluating zanzalintinib in combination with pembrolizumab in the maintenance
setting in squamous NSCLC. The primary endpoint of the trial is six-month PFS
(PFS-6), with secondary endpoints including safety, PFS, OS, ORR and duration of
response (DOR). The study is currently enrolling.
Enrollment Ongoing in Phase 2 STELLAR-201 Trial in Recurrent Meningioma.
Enrollment is ongoing for the phase 2 STELLAR-201 trial. Initiated in April
2026, STELLAR-201 is evaluating zanzalintinib in patients with recurrent Grade
I/II/III meningioma with relapse or progression following radiation and/or
surgery or those who are not candidates for these therapies. The primary
endpoint of the trial is ORR, with secondary endpoints
- more -
Exelixis Third Quarter 2026 Financial Results
October 29, 2026 Page 5 of 9
──────────────────────────────────────────────────────────────
including PFS, DOR and OS. Pending favorable results, the trial represents an
opportunity for zanzalintinib to become the first and only systemic therapy for
this form of meningioma, the most common primary intracranial neoplasm for which
there are currently no approved systemic therapies.
Corporate Highlights
Stock Repurchase Program (SRP) Update.
In May 2026, Exelixis’ Board of Directors authorized the repurchase of up to
$750 million of the company’s outstanding common stock before December 31, 2027
(May 2026 SRP). As of the end of the third quarter of 2026, Exelixis repurchased
$402.1 million of the company’s outstanding common stock, at an average price of
$54.03 per share under the May 2026 SRP. Since Exelixis’ Board of Directors
authorized the first SRP in March 2023, Exelixis has repurchased a total of $3.2
billion of the company’s outstanding common stock, retiring 97.8 million shares,
at an average price of $32.25 per share, as of the end of the third quarter of
2026.
Stock repurchases under the May 2026 SRP may be made from time to time through a
variety of methods, which may include open market purchases, in block trades,
Rule 10b5-1 trading plans, accelerated share repurchase transactions, exchange
transactions, or any combination of such methods. The timing and amount of any
stock repurchases under the program will be based on a variety of factors,
including ongoing assessments of the capital needs of the business, alternative
investment opportunities, the market price of our common stock and general
market conditions. The program does not obligate us to acquire any amount of our
common stock, and may be modified, suspended or discontinued at any time without
prior notice.
Announcement of Settlement with Azurity Pharmaceuticals, Inc. (Azurity). On
October 28, 2026, we entered into a settlement and license agreement with
Azurity (the Azurity Settlement Agreement) to resolve the Azurity litigation.
Pursuant to the terms of the Azurity Settlement Agreement, we will grant Azurity
a license to market its proposed 505(b)(2) NDA product in the U.S. beginning on
December 1, 2030, if approved by the FDA and subject to conditions and
exceptions customary for agreements of this type. The effective date for the
proposed generic cabozantinib products where we have a settlement and license
agreement remains January 1, 2031, subject to conditions and exceptions
customary for agreements of this type.
Announcement on Patent Litigation Trial Appeal with MSN Laboratories. In August
2026, the U.S. Court of Appeals for the Federal Circuit (Court of Appeals)
affirmed a favorable district court decision in Exelixis’ patent lawsuit against
MSN Laboratories Private Limited et al. (MSN), upholding the validity of U.S.
Patent Nos. 11,091,439, 11,091,440 and 11,098,015. As a result, the effective
date of any final FDA approval of MSN’s Abbreviated New Drug Application (ANDA)
shall not be a date earlier than January 15, 2030, subject to any further
appellate proceedings, applicable regulatory exclusivity, and the outcome of
separate consolidated litigation involving U.S. Patent No. 12,128,039, with a
trial scheduled for November 2026. The Court of Appeals also dismissed as moot
MSN’s appeal relating to the validity of U.S. Patent No. 11,298,349.
Basis of Presentation
Exelixis uses a 52- or 53-week fiscal year that generally ends on the Friday
closest to December 31. For convenience, references in this press release as of
and for the fiscal periods ended October 2, 2026 and October 3, 2025, are
indicated as being as of and for the periods ended September 30, 2026 and
September 30, 2025, respectively.
Conference Call and Webcast
Exelixis management will discuss the company’s financial results for the third
quarter of 2026 and provide a general business update during a conference call
beginning at 5:00 p.m. ET / 2:00 p.m. PT today, Thursday, October 29, 2026.
- more -
Exelixis Third Quarter 2026 Financial Results
October 29, 2026 Page 6 of 9
──────────────────────────────────────────────────────────────
To access the conference call, please register using this link . Upon
registration, a dial-in number and unique PIN will be provided to join the call.
To access the live webcast link, log onto www.exelixis.com and proceed to the
Event Calendar page under the Investors & News heading. A webcast replay of the
conference call will also be archived on www.exelixis.com for one year.
About Exelixis
Exelixis is a globally ambitious oncology company innovating next-generation
medicines and regimens at the forefront of cancer care. Powered by drug
discovery and development excellence, we are rapidly evolving our product
portfolio to target an expanding range of tumor types and indications with our
clinically differentiated pipeline of small molecules and biotherapeutics. This
comprehensive approach harnesses decades of robust investment in our science and
partnerships to advance our pipeline of franchise molecules, including our novel
oral kinase inhibitor zanzalintinib, and to extend the impact of our flagship
commercial product, CABOMETYX ® (cabozantinib). Exelixis is driven by a bold
scientific pursuit to create transformational treatments that give more patients
hope for the future. For information about the company and its mission to help
cancer patients recover stronger and live longer, visit www.exelixis.com ,
follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow
Exelixis on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements, including, without
limitation, statements related to: Exelixis’ belief in zanzalintinib as its next
potential franchise opportunity; Exelixis’ focus on disciplined capital
deployment, including investing in its R&D portfolio, returning value to
shareholders through its stock repurchase programs, and evaluating external
innovation opportunities that may strengthen its pipeline and create long-term
value; Exelixis’ clinical development plans for zanzalintinib, including
progress on additional pivotal trials and plans to share progress when
appropriate; Exelixis’ plans to present detailed findings from the NLM
subpopulation for STELLAR-303 at a future medical conference; the anticipated
timing of topline results from STELLAR-304; Exelixis’ belief that, pending
favorable results, STELLAR-201 represents an opportunity for zanzalintinib to
become the first and only systemic therapy for recurrent Grade I/II/III
meningioma; Exelixis’ expectations regarding the timing and outcome of FDA
review of its NDA for zanzalintinib in combination with atezolizumab for
previously treated metastatic CRC; Exelixis’ expectations regarding the
implications of the appellate ruling in its patent litigation with MSN for the
timing of any final FDA approval and U.S. commercial launch of MSN’s proposed
ANDA product, subject to any further appellate proceedings, applicable
regulatory exclusivity, and the outcome of its separate consolidated litigation
with MSN; Exelixis’ expectations regarding the licenses to be granted and the
timing of U.S. market entry for Azurity’s proposed 505(b)(2) NDA product and
proposed generic cabozantinib products under its settlement and license
agreements, subject to FDA approval and the applicable terms, conditions, and
exceptions of those agreements; Exelixis’ updated FY 2026 financial guidance;
the timing and amount of any future stock repurchases under the May 2026 SRP and
the potential modification, suspension, or discontinuation of the program;
Exelixis’ scientific pursuit to create transformational treatments that give
more patients hope for the future; and other statements that are not historical
facts. Any statements that refer to expectations, projections, or other
characterizations of future events or circumstances are forward-looking
statements and are based upon Exelixis’ current plans, assumptions, beliefs,
expectations, estimates, and projections. Forward-looking statements involve
risks and uncertainties. Actual results and the timing of events could differ
materially from those anticipated in the forward-looking statements as a result
of these risks and uncertainties, which include, without limitation: the degree
of market acceptance of CABOMETYX and other Exelixis products in the indications
for which they are approved and in the territories where they are approved, and
Exelixis’ and its partners’ ability to obtain or maintain coverage and
reimbursement for these products; the effectiveness of CABOMETYX and other
Exelixis products in comparison to competing products; complexities and the
unpredictability of regulatory review and approval processes in the U.S. and
elsewhere, including the timing and outcome of FDA review of Exelixis’ NDA for
zanzalintinib in combination with atezolizumab for
- more -
Exelixis Third Quarter 2026 Financial Results
October 29, 2026 Page 7 of 9
──────────────────────────────────────────────────────────────
previously treated metastatic CRC and the risk that the FDA may require
additional information or analyses, further extend its review, or may not
approve the NDA in a timely fashion, if at all; the level of costs associated
with Exelixis’ commercialization, research and development, in-licensing or
acquisition of product candidates, and other activities; Exelixis’ ability to
identify, evaluate and successfully execute external innovation and other
business development opportunities and to realize the anticipated benefits of
any such opportunities; Exelixis’ ability to maintain and scale adequate sales,
marketing, market access and product distribution capabilities for its products
or to enter into and maintain agreements with third parties to do so; the
availability of data at the referenced times; the potential failure of
cabozantinib, zanzalintinib and other Exelixis product candidates, both alone
and in combination with other therapies, to demonstrate safety and/or efficacy
in clinical testing; uncertainties inherent in the drug discovery and product
development process; Exelixis’ dependence on its relationships with its
collaboration partners, including their pursuit of regulatory approvals for
partnered compounds in new indications, their adherence to their obligations
under relevant collaboration agreements and the level of their investment in the
resources necessary to complete clinical trials or successfully commercialize
partnered compounds in the territories where they are approved; Exelixis’
continuing compliance with applicable legal and regulatory requirements;
unexpected concerns that may arise as a result of the occurrence of adverse
safety events or additional data analyses of clinical trials evaluating
cabozantinib, zanzalintinib and other Exelixis product candidates; Exelixis’
dependence on third-party vendors for the development, manufacture and supply of
its products and product candidates; Exelixis’ ability to protect its
intellectual property rights; market competition, including the potential for
competitors to obtain approval for and market generic versions, or other
products that compete with, of Exelixis’ marketed products; changes in economic
and business conditions, including as a result of changing trade policies and
tariffs and the related uncertainty thereof; and other factors detailed from
time to time under the caption “Risk Factors” in Exelixis’ most recent Annual
Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in
Exelixis’ other future filings with the Securities and Exchange Commission. All
forward-looking statements in this press release are based on information
available to Exelixis as of the date of this press release, and Exelixis
undertakes no obligation to update or revise any forward-looking statements
contained herein, except as required by law.
Exelixis, the Exelixis logo, CABOMETYX and COMETRIQ are registered U.S.
trademarks of Exelixis, Inc.
Tecentriq ® (atezolizumab) is a registered trademark of Genentech, a member of
the Roche Group.
WELIREG ® and KEYTRUDA QLEX ™ are registered trademarks of Merck Sharp & Dohme
LLC,
a subsidiary of Merck & Co., Inc., Rahway, N.J., USA.
-see attached financial tables-
- more -
Exelixis Third Quarter 2026 Financial Results
October 29, 2026 Page 8 of 9
──────────────────────────────────────────────────────────────
EXELIXIS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except per share amounts)
(unaudited)
Three Nine
Months Months
Ended Ended
Septem… Septe…
30, 30,
Reve… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net
prod… $ 604,9… $ 542,930 $ 1,732,… $ 1,576…
reve…
Coll… 53,772 54,825 165,272 145,2…
reve…
Total 658,6… 597,755 1,898,… 1,721…
reve…
Oper…
expe…
Cost
of 26,233 18,574 66,843 57,216
goods
sold
Rese…
and 209,4… 199,164 621,384 611,7…
deve…
Sell…
gene… 154,5… 123,661 441,793 395,7…
and
admi…
Rest… — 19,816 — 19,816
Total
oper… 390,2… 361,215 1,130,… 1,084…
expe…
Inco…
from 268,4… 236,540 768,178 636,9…
oper…
Inte… 14,315 15,922 44,652 51,787
inco…
Other
inco… 47 -49 320 -244
(exp…
net
Inco…
befo… 282,7… 252,413 813,150 688,5…
inco…
taxes
Prov…
for 64,690 58,835 172,538 150,4…
inco…
taxes
Net $ 218,0… $ 193,578 $ 640,612 $ 538,0…
inco…
Net
inco…
per
shar…
Basic $ 0.88 $ 0.72 $ 2.54 $ 1.97
Dilu… $ 0.85 $ 0.69 $ 2.46 $ 1.90
Weig…
comm…
shar…
outs…
Basic 246,7… 268,421 251,964 273,2…
Dilu… 255,7… 278,535 260,917 283,7…
- more -
Exelixis Third Quarter 2026 Financial Results
October 29, 2026 Page 9 of 9
──────────────────────────────────────────────────────────────
EXELIXIS, INC.
RECONCILIATION OF GAAP NET INCOME TO NON-GAAP NET INCOME
(in thousands, except per share amounts)
(unaudited)
Three Nine
Months Months
Ended Ended
Septem… Septemb…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
GAAP
net $ 218,095 $ 193,578 $ 640,612 $ 538,042
income
Adjust…
Stock-…
compen…
- 11,069 10,353 35,731 34,018
resear…
and
develo…
Stock-…
compen…
-
sellin… 17,649 20,532 54,600 58,868
general
and
admini…
Income
tax
effect -6,588 -6,569 -20,857 -20,917
of the
above
adjust…
Non-GA…
net $ 240,225 $ 217,894 $ 710,086 $ 610,011
income
GAAP
net
income
per
share:
Basic $ 0.88 $ 0.72 $ 2.54 $ 1.97
Diluted $ 0.85 $ 0.69 $ 2.46 $ 1.90
Non-GA…
net
income
per
share:
Basic $ 0.97 $ 0.81 $ 2.82 $ 2.23
Diluted $ 0.94 $ 0.78 $ 2.72 $ 2.15
Weight…
common
shares
outsta…
Basic 246,756 268,421 251,964 273,269
Diluted 255,754 278,535 260,917 283,701
____________________
(1) Non-cash stock-based compensation used for GAAP reporting in accordance with
Accounting Standards Codification Topic 718, Compensation—Stock Compensation .